



(86) Date de dépôt PCT/PCT Filing Date: 2008/09/12
(87) Date publication PCT/PCT Publication Date: 2009/03/19
(85) Entrée phase nationale/National Entry: 2010/03/11
(86) N° demande PCT/PCT Application No.: EP 2008/007579
(87) N° publication PCT/PCT Publication No.: 2009/033715
(30) Priorités/Priorities: 2007/09/14 (EP07018131.8);
2008/04/03 (EP08006810.9)

(51) Cl.Int./Int.Cl. *C07K 14/00* (2006.01),
A61K 9/00 (2006.01), *A61P 19/02* (2006.01),
C12N 5/00 (2006.01)

(71) Demandeur/Applicant:
SCIL TECHNOLOGY GMBH, DE

(72) Inventeurs/Inventors:
BOSSERHOFF, ANJA, DE;
SCHUBERT, THOMAS, DE;
HUSTERT, ELISABETH, DE

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : FACTEURS NEUROENDOCRINAUX POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
(54) Title: NEUROENDOCRINE FACTORS FOR TREATMENT OF DEGENERATIVE DISEASES

(57) **Abrégé/Abstract:**

The present invention is related to the use of a repellent factor and/or polypeptide for manufacturing of a pharmaceutical composition for treating a disease such as a degenerative disease in particular to the use of a SLIT3 or NETRI N1 protein therefore. The invention is further related to a polypeptide fragment of SLIT3, a pharmaceutical composition comprising the polypeptide and the use thereof.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 March 2009 (19.03.2009)

PCT

(10) International Publication Number
WO 2009/033715 A2

(51) International Patent Classification:

C07K 14/00 (2006.01) **C12N 5/00** (2006.01)
A61K 9/00 (2006.01) **A61P 19/02** (2006.01)

(21) International Application Number:

PCT/EP2008/007579

(22) International Filing Date:

12 September 2008 (12.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

07018131.8 14 September 2007 (14.09.2007) EP
08006810.9 3 April 2008 (03.04.2008) EP

(71) **Applicant** (*for all designated States except US*): **SCIL TECHNOLOGY GMBH** [DE/DE]; Fraunhoferstrasse 15, 82152 Martinsried (DE).

(72) Inventors; and

(75) **Inventors/Applicants** (*for US only*): **BOSSERHOFF, Anja** [DE/DE]; Rauberstrasse 15c, 93053 Regensburg (DE). **SCHUBERT, Thomas** [DE/DE]; Rat-Beil-Strasse 43, 60318 Frankfurt (DE). **HUSTERT, Elisabeth** [DE/DE]; Wittelsbacherstrasse 7, 82110 Germering (DE).

(74) **Agents:** **JORDAN, V.** et al.; Weickmann & Weickmann, Postfach 860 820, 81635 München (DE).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) **Title:** NEUROENDOCRINE FACTORS FOR TREATMENT OF DEGENERATIVE DISEASES

(57) **Abstract:** The present invention is related to the use of a repellent factor and/or polypeptide for manufacturing of a pharmaceutical composition for treating a disease such as a degenerative disease in particular to the use of a SLIT3 or NETRI N1 protein therefore. The invention is further related to a polypeptide fragment of SLIT3, a pharmaceutical composition comprising the polypeptide and the use thereof.



WO 2009/033715 A2

Neuroendocrine factors for treatment of degenerative diseases

Description

5 The present invention is related to the use of a repellent factor and/or polypeptide, in particular of a NETRIN1, SLIT3 protein or fragments thereof for manufacturing of a pharmaceutical composition for treating or preventing degenerative diseases in particular cartilage defects. The invention is further related to a polypeptide fragment of SLIT3, a pharmaceutical composition
10 comprising the polypeptide and the use thereof.

Cartilage repair and regeneration in traumatic and degenerative joint diseases remains still a major challenge in orthopaedics. Cartilage injuries and degenerative disorders play a major reason which creates significant
15 pain and gradual loss of joint function with disability and immobility in the adult population. The intrinsic repair capabilities of cartilage are limited owing to the low mitotic potential of chondrocytes *in vivo* and the resulting tissue produced in adults is generally inferior to normal cartilage. It is generally believed that damaged cartilage does not receive sufficient stimuli
20 to elicit a repair response because cartilage e.g. articular cartilage lacks a vasculature. Chondrocytes in cartilaginous tissue are normally not exposed to sufficient amount of repair stimulating agents such as growth factors and fibrin clots present in damaged vascularised tissue.

The functional integrity of joints depends on strict separation of the
25 compartment borders. Crossing of the joint compartment boundaries and destruction of the cartilage compartment is found in inflammatory and degenerative joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA).

Frequently cartilage disorders (e.g. rheumatoid arthritis) are characterized or
30 aggravated by the invasive and destructive behaviour of cell populations

-2-

from surrounding tissue compartments such as synovial tissue fibroblast (SF) cells migrating in from synovial tissue. The destruction of articular structures of the joint, like cartilage and bone, through synovial fibroblasts (SF) is a crucial event in RA and OA (Pap, 2003; Pap, 2007; Yasuda, 2006; Huber, et al., 2006).

Numerous strategies to inhibit further progression of the destructive structural changes as well as novel approaches to reverse the disease by regenerative treatment of diseased cartilage including finding of new agents that have the potential to repair destructed cartilage have been performed with varying degree of success. These strategies include marrow-stimulation techniques, autologous and allogenic transplantation, autologous chondrocyte transplantation, periosteal grafting, prdie drilling, abrasion chondroplasty, including microfracturing and mosaicplasty. However, these procedures are not reliable and are limited to small- and medium- sized focal chondral and osteochondral defects. Mosaicplasty is limited by the need to create defects at donor sites, by an insufficient repair result and by technical difficulties experienced in resurfacing the original curvature of the joint (Kuroda, et al., 2007). The autologous chondrocyte transplantation techniques has several disadvantages which includes lack of sufficient number of chondrocytes, necessity of creation of donor site defects, poor efficacy and high treatment costs.

Several growth factors like TGF- β 1, FGF-2, IGF-1, TP-508, OP-1 or other BMPs including GDFs or combinations thereof have been identified that induce the proliferation and differentiation of progenitor cells into functional bone and/or cartilage tissue. In particular, TGF- β 1 has been shown to promote chondrogenic differentiation of progenitor cells and to enhance chondrocyte differentiation. IGF-1 primarily acts in an anabolic fashion to increase proteoglycan and type II collagen synthesis. However, these growth factors are rather unspecific having the risk for undesired side effects. Others such as BMPs have the potential to induce osteogenic genes and therefore induce undesired bone formation. Another limitation of the application of this growth factor technology is the relatively short biological

-3-

half-life of the exogenous growth factor that would enable only transient biological effects after their delivery.

Pro-inflammatory cytokines, proteases and metalloproteinases are likely responsible for some signs and symptoms as well as structural changes present in OA and RA patients. The inhibition of the synthesis/activity of these enzymes as a treatment for OA and RA have been the focus of intensive research.

To date, the most promising strategy is still the use of small chemical entities that can block the activity of MMPs. However, MMP inhibitors could produce side effects and have not yet demonstrated a major reduction in the progression of the disease.

In addition, other new strategies are currently under development which are cited below.

US2003068705 discloses three hundred and five nucleic acids encoding PRO polypeptides of which some (e.g. IL-17 homologous or related polypeptides) are allegedly useful for stimulating the proliferation or differentiation of chondrocytes and as such may be used in the treatment of various bone and/or cartilage disorders such as sport injuries or arthritis.

WO20001090357 provides proteins for the treatment of developmental defects, inflammatory disease, or for modulating immune responses.

US2003044917 relates to human PRO polypeptides for stimulating the proliferation and differentiation of chondrocytes and their use in the treatment of various bone and/or cartilage diseases such as arthritis and sports injuries. However, only sequence 6029 was tested positive.

Another class of proteins such as axonal guidance molecules (e.g. Netrins, Slits) has been suggested for modulating inflammatory cell movement (WO0164837, WO05074556, WO00055321, WO0190357). WO0164837, WO03075860, WO06019904 and US 2006/0153840 disclose methods for promoting angiogenesis, proliferation and/or promoting migration of cells for treatment of neuropathy and cancer.

-4-

WO2002081745 teaches the use of SLIT3 for diagnosis of osteoporosis/bone disease, promoting osteogenesis and/or preventing osteoporosis/bone disease.

5 WO99/23219, JP11164690 and JP11075846 disclose the human SLIT3 polypeptide sequence.

WO00/55321 discloses vertebrate SLIT DNA sequences (i.e. Xenopus and human Slit2), protein and uses thereof.

10 However, none of the methods and compositions disclosed in the art demonstrates a major reduction in the progression of the treated disease without side effects or results in abolishment of destructive processes and actual repair and replacement of cartilage tissue.

15 Therefore, there is a need for compositions and uses thereof for an improved treatment and/or prevention of progressive cartilage destruction, in particular, after trauma and in case of chronic diseases such as full-thickness defects and superficial defects and arthritis (e.g. osteoarthritis, rheumatoid arthritis), meniscal tears, anterior crucial ligament (ACL)-injury, which overcome the problems associated with the currently available methods and compositions.

20 Therefore, an object of the present invention is to provide means for repairing or regeneration of cartilage defects and/or inhibition of the disease progression of cartilage diseases or disorders such as arthritis and sport injuries.

Another object of the present invention is to provide means for inhibition of synovial cell migration and therefore inhibition of cartilage destruction.

25 Another object of the present invention is to provide means, which are suitable in the treatment of cartilage diseases and more particularly inflammatory cartilage diseases and diseases with involvement of synovial fibroblast invasion or pannus formation.

Another object of the present invention is to provide a composition and use

-5-

thereof for attraction/chemotaxis of mesenchymal stem cells from the surrounding for cartilage regeneration.

Another object of the present invention is to provide compositions and uses thereof for the induction of cartilage formation and/or stimulating the proliferation or differentiation of chondrocytes.

The problem underlying the present invention is solved by the use of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect. The invention, in particular, relates to the use of a repellent factor for manufacturing of a pharmaceutical composition for the prevention and/or treatment of a degenerative disease, preferably a degenerative cartilage disease a) associated with infiltration or migration of synovial fibroblasts preferably into articular or non-articular cartilage and/or associated with pannus formation, or b) associated with decreased attachment of cells preferably fibroblast or synovial fibroblast cells to articular or non-articular cartilage. In particular, the repellent factor modulates or inhibits the migration of fibroblast-like cells such as synovial fibroblast cells, inhibition of synovial cell hyperplasia and/or promotes migration, proliferation and/or differentiation of mesenchymal stem cells and/or chondrocytes for cartilage induction and/or regeneration and thereby alters, inhibits, prevents and/or treats the progression of the degenerative disease. In particular, the repellent factor inhibits, alters or prevents osteophyte formation, preferably in a patient.

In particular, the invention relates to the use of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect, wherein the repellent factor is a fragment of SLIT3 (SEQ ID NO:1). The fragment preferably has a length of ≤ 1523 AA, preferably ≤ 1200 AA, more preferably ≤ 1000 AA and most preferably ≤ 800 AA and, in particular, ≥ 20 AA, preferably ≥ 50 AA, more preferably ≥ 100 AA. Preferably, the fragment of SLIT3 comprises the sequence of SEQ ID NO:1 from position 34 to 917, position 47 to 863, position 66 to 857, position

-6-

279 to 863, position 279 to 857, position 279 to 724, position 279 to 504, position 311 to 432, position 335 to 432 or position 312 to 437. According to the invention it has been found that repellent factors, in particular, SLIT3 are expressed at the cartilage compartment borders where they maintain the integrity of the articular cartilage. Further repellent factors inhibit migration of fibroblasts, nerve fibers and vessels into articular cartilage. Since invasion of pannus tissue into cartilage in chronic joint disease is only possible after altered repellent factor expression, this invasion can be modulated by repellent factors, in particular, by SLIT3 and, consequently, degenerative diseases associated therewith can be treated.

The inventors have demonstrated that members of the repellent factors and their receptors are differentially expressed in synovial fibroblasts of patient suffering from degenerative diseases such as osteoarthritis and arthritis. This was analyzed by gene quantitative RT-PCR performed on a Lightcycler of cDNA isolated from cultured primary human synovial fibroblasts. ROBOs and SLITs are similarly expressed in synovial fibroblasts of osteoarthritis (OASF) patients and synovial fibroblasts of rheumatoid arthritis (RASf) patients except of ROBO3 mRNA expression which was strikingly enhanced in RASf compared to a very weak expression in OASF. SLIT1 mRNA levels are clearly lowered compared to SLIT2 or SLIT3, but expression of SLITs in OASF appears to be generally higher than in RASf.

ROBO1 and ROBO2 are expressed both in differentiated and OA chondrocytes, but expression in OA chondrocytes is 10-fold (ROBO1) and even 100-fold (ROBO2) increased compared to differentiated chondrocytes. No expression of ROBO3 was measured in both cell types. All three SLITs are expressed in differentiated and OA chondrocytes, finding again higher levels in OA than in differentiated chondrocytes.

UNC5B and UNC5C were significantly upregulated in synovial fibroblasts of OA and RA patients.

Further, it has been found that the significant loss of ROBO3 expression in RASf in higher passages of synovial fibroblast cells might be an important

-7-

step in loosing repulsive activity towards SLIT3. These findings presented by the inventors suggest that deregulation of the ROBO3 receptor in synovial fibroblasts in RA (and OA) correlates with aggressiveness of the fibroblasts.

Furthermore, the invention is based on the finding that repellent factors such as NETRIN1, SLIT3 as well as fragments thereof are involved in regulation of the aggressive behaviour of cells such as synovial fibroblasts cells and migration of these cells to or into cartilage, which is a major problem in degenerative diseases such as rheumatoid arthritis. Without being limited to specific molecules, the invention is based on the finding that repellent factors such as NETRIN1 and SLIT3 and fragments thereof inhibit the migration of OASF and RASF cells. Due to this surprising finding, repellent factors can be used for the treatment of a variety of diseases which are subject to the migration and infiltration of cells including altered migration of fibroblast-like cells such as synovial fibroblast cells and/or pannus formation which can't subsequently cause destruction or altered function of a tissue such as articular or non-articular cartilage. In view of the surprising finding disclosed herein, repellent factors can be used as a medicament for the prevention and/or treatment of various diseases and disease conditions described herein. Respective diseases are, among others, degenerative preferably cartilage diseases such as degenerative joint and/or disc diseases including those further described above. In particular, according to the invention, the disease is selected from degenerative disc disease, meniscus tears, anterior crucial ligament (ACL) injury, arthritis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, rhizomelic pseudoarthritis, rheumatoid polyarthritis, synovitis or villonodular synovitis.

According to the invention cartilage defects or cartilage diseases can be prevented or treated.

Another finding of the inventors was the influence of repellent factors on the migratory behavior of human mesenchymal stem cells which are known for their ability to differentiate into chondrocytes. Induction of migration was observed using a Boyden Chamber assay after adding factors such as

-8-

NETRIN1 to the lower chamber, indicating that repellent factors can act as a chemoattractant for mesenchymal stem cells such as synovial membrane or lining cells. In view of this finding, not only the destructive behavior of migratory cells can be inhibited but also cells for regeneration of destructed
5 tissue can be attracted. Repellent factors therefore further improve the treatment of degenerative diseases.

A further finding was the induced differentiation of human mesenchymal stem cells towards a chondrogenic cell lineage showing that repellent factors such as SLIT3 can induce chondrogenesis and therefore are useful for
10 regeneration and treatment of cartilage diseases.

Therefore, the invention encompasses the use of repellent factors for manufacturing a pharmaceutical composition for treatment of a cartilage defect, in particular, a degenerative disease in a patient caused by
15 aggressive fibroblast cells by administration of an effective amount of a repellent factor that modulates the migration, proliferation and/or attachment of cells to cartilage.

Preferably, an effective amount of a repellent factor administered to a patient is from 0.001 mg/kg body weight of patient to 100 mg/kg body weight of
20 patient, preferably 0,01 mg/kg body weight of patient to 20 mg/kg body weight of patient, more preferably from 0.01 to 10 mg/kg body weight of patient, most preferably 0,1 mg/kg to 1 mg/kg body weight of patient.

For the purpose of the present invention, the term "repellent factor" means an active agent, which at a certain concentration or concentration range is
25 able to inhibit the migration of cells across a tissue boundary e.g. the cartilage boundary. As such for example the migration of aggressive synovial fibroblasts into the cartilage and/or bone can be inhibited or altered. It also includes inhibition or further progression of pannus formation or pannus invasion into cartilage. Repellent factors can alter the sprouting of
30 nerve fibers as axon guiding cues for example by repellent or attractant activities.

-9-

Repellent factors comprise a large number of molecules also known as axon guidance molecules which modulate axonal outgrowth in the nervous system. They include NETRINS, SLITs, SEMAPHORINS and EPHRINS and its receptors NEUROPILIN, ROUNDABOUTs (ROBOs), and members of the
5 UNC5 and DCC families (Klagsbrun and Eichmann, 2005).

NETRINS are a family of secreted proteins with homology to laminin domains. This family consists of NETRIN1, 2, 3 und 4. They contain a laminin-VI domain, EGF-like repeats and a heparin-binding C-terminal domain. Netrin receptors are the deleted in colorectal cancer (DCC) receptor
10 family, which consists of DCC and neogenin, or the uncoordinated-5 (UNC5) family, which comprises UNC5A, 5B, 5C, 5D. Netrins have been implicated in angiogenesis, and during morphogenesis such as lung branching, mammary gland development and tumorigenesis. NETRIN binding to DCC and neogenin was shown to lead to cell attraction whereas binding to the
15 UNC receptor modulates repulsion.

SLITs were originally identified in *Drosophila* as axon guidance molecules. Mammalian SLIT1, SLIT2 and SLIT3 orthologs are large secreted proteins with four leucine-rich repeat (LRR) domains, nine EGF domains, a laminin G (LamG) domain, and C-terminal cystine knot. SLIT1 mRNA is expressed in
20 brain, anaplastic oligodendroglioma, and Jurkat T cells. SLIT2 and SLIT3 mRNAs are co-expressed in embryonic stem (ES) cells with embryoid body formation (Kato and Kato, 2005; Vargesson, et al., 2001). Slit3, but not Slit2, is localized within the mitochondria which implies that Slit3 has potentially unique functions not shared by other Slit proteins (Little, et al.,
25 2001). Slits act by binding to Roundabout receptors. There are four human Robo transmembrane receptors (Robo1, Robo2, Robo3 and Robo4) that share fibronectin type III and immunoglobulin-like domains (Ig), but vary in their cytoplasmic domains (Itoh, et al., 1998; Howitt, et al., 2004; Hohenester, et al., 2006). Slit proteins are primarily known to be involved in
30 regulating cell-cell interactions and cell-matrix interactions of migrating cells during embryonic development and by mediating axon guidance through attraction or repulsion of growth cones. Over the last decade, the Robo-/ Slit

-10-

system has also been described to mediate cell adhesion and induce tumor angiogenesis. Slits are also implicated in other developmental processes such as muscle precursor cell migration in drosophila, leucocyte trafficking and kidney induction (Klagsbrun and Eichmann, 2005).

- 5 Semaphorins are surface or locally secreted nerve repellent factors with a specific repellent action on nerve fibers via distinct surface receptors such as neuropilin 1 and neuropilin 2. Class III Semaphorins include SEMA A, B, C, and F. Ephrins and their receptors Eph represent ligands and tyrosine kinase receptors implicated in a variety of developmental processes
- 10 including the nervous system development and angiogenesis. Ephrin A ligands (Ephrin A1, A2, A3, A4, A5) are GPI anchored molecules which bind to EphA receptors, whereas Ephrin B proteins (Ephrin B1-3) bind to Eph B receptors. Ephrins can also vice versa function as receptors which are bound by Ephs as ligands.
- 15 In some embodiment, the repellent factor of the present invention is an agonist or antagonist of a ROUNDABOUT receptor (e.g. ROBO1, 2, 3), Deleted in Colon Cancer (e.g. DCC) or UNC (e.g. UNC5A-D) receptor. As used herein, the agonist or antagonist activates or inhibits the activity of a ROUNDABOUT receptor, DCC or UNC receptor, which preferably is the
- 20 signal transduced by the interaction between the receptor and the ligand or the inhibition of a signal that is transduced by the receptor which is not occupied by the ligand.

In some preferred embodiments, the agonist, antagonist and/or repellent factor of the present invention is selected from the group of NETRINS (such

25 as NETRIN1, NETRIN2, NETRIN4, NETRIN5), SLITs (such as SLIT1, SLIT2, SLIT3), EPHRINS (such as EPHRIN A2, A4, A5) and SEMAPHORINS (such as SEMAPHORIN 3A, 3B, 3C and 3F), fragments thereof and amino acid sequences thereof.

The term "treating or treatment" as used herein, means an alleviation of a

30 disorder or disease or an alleviation of symptoms associated with a disorder or disease, halt of further progression or worsening of the symptoms.

-11-

The term "prevention" includes prevention or prophylaxis of the disease or disorder.

5 The term "cartilage defect" refers to any cartilage abnormality including cartilage diseases, alteration of cartilage caused e.g. by trauma or degenerative processes.

10 The term "degenerative diseases" means diseases or defects with impaired cartilage structure such as cartilage degeneration or destruction with or without involvement of bony structures. Preferably, degenerative diseases are degenerative cartilage diseases. These include temporomandibular joint disorder (TMDs), acetabular labrum disorders, arthritis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, rhizomelic pseudoarthritis, rheumatoid polyarthritis, degenerative disc disease, osteochondral defects, superficial chondral defects, osteochondritis dissecans, full-thickness chondral defects, partial-thickness chondral defects, meniscus tears, anterior crucial ligament injury, synovial osteochondromatosis, ankylosing spondylitis, synovitis, villonodulat synovitis.

The terms cartilage defect and degenerative diseases as used herein, in particular, do not include osteoporosis.

20 The term "degenerative disc disease (DDD)" is a chronic process characterized in part by progressive loss of proteoglycan and water content in the nucleus pulposus of one or more discs that can become manifest in multiple disorders such as idiopathic low back pain, disc herniation, internal disc disruption or fissured discs, radiculopathy, spinal stenosis, herniated nucleus pulposus-induced sciatica, sciatica, idiopathic scoliosis and/or myelopathy. The disc degeneration grade can be ranked by analysis of preoperative MRI.

25 The term "articular cartilage" covers the surface of the portion of bones in joints and functions as a cushion between two bones to allow movement in joints. Normal healthy cartilage is described as hyaline cartilage. Articular

30

-12-

cartilage consists of specialized cells (chondrocytes) embedded into a matrix of intracellular material rich in proteoglycans, predominantly aggrecan, collagen type II fibrils, other proteins and water. The matrix is produced and maintained by the chondrocytes embedded within. Cartilage tissue is not innervated and vascularised and is nourished by the underlying tissue.

Non-articular cartilage does not cover articulating surfaces and includes fibrocartilage (including interarticular fibrocartilage e.g. the meniscus and fibrocartilage of the intervertebral disc) and elastic cartilage.

The term "synovial cells", "synovium" or "synovial fibroblasts" as used herein, refers to a cell physiologically associated with the synovial membrane or present in the synovial space; a cell obtained from the joint's synovial membrane or synovial fluid. It also refers to cellular lining covering the non-cartilaginous surfaces of the synovial joints. The synovium consist of the synovial lining cell and the synovial subling (subsynovium), which merges with the joint capsule.

The term "pannus tissue" means a proliferation of synovial cells and/or an erosion of tissue such as a deposit of cells or material onto cartilage (e.g. articular cartilage), an invasion or destruction of articular cartilage with or without involvement of the subchondral region. Also included is an invasion of cells into the subchondral bone marrow.

In a preferred embodiment the problem underlying the present invention is solved by the use of a repellent factor for manufacturing of a pharmaceutical composition for the prevention and/or treatment of a degenerative disease which preferably is not osteoporosis, wherein the repellent factor is selected from the group consisting of polypeptides having a sequence which a) has at least 85% homology, preferably 90%, 95% homology, more preferably identity to the amino acid sequence of SLIT3 (SEQ ID NO: 1) or NETRIN1 (SEQ ID NO: 10), b) is an active fragment of SLIT3 or NETRIN1 or c) has at least 85%, 90%, 95% homology to the amino acid sequence of the active fragment of b).

-13-

The term "active fragment" preferably means an activity of the polypeptide to bind to the same receptor or binding partner as the mature full-length polypeptide e.g. the mature SLIT3 polypeptide. Binding for example may activate or inhibit the receptor and downstream cascade. SLIT3 fragment activity can for example be determined by binding to its ROBO receptor using methods known in the art such as a Biacore binding assay, an in vitro pulldown assay as described in (Marlot et al., 2007), ELISA protein binding assay or immunoprecipitation. Activity of the fragment can also be determined using an assay as described within Examples 2, 3, 4, 6, 7 or 9 of the invention e.g. Boyden Chamber migration assay, proliferation assay or an *in vivo* functional assay such as described in Examples 6 and 7.

To determine the percent homology of two amino acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues at corresponding amino acid positions are then compared. When a position in one sequence is occupied by the same amino acid residue as the corresponding position in the other sequence, then the molecules are homologous at that position.

The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = numbers of identical positions/total numbers of positions x 100).

In addition to the above-described methods, a determination of the percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990 Proc. Natl. Acad. Sci. USA 90:5873-5877). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990 J. Mol. Biol. 215:403-410).

BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to CCSRPs of the present invention. To obtain gapped alignments for

-14-

comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997 Nucleic Acids Res. 25:3389-3402). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. Another preferred non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (CABIOS 1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) that is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4 can be used to obtain amino acid sequences homologous to the CCSRPs of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997 Nucleic Acids Res. 25:3389-3402). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. Another preferred non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (CABIOS 1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) that is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4 can be used.

Fragments preferably have a length of less than 1523 or 1522 amino acids, preferably of less than 1491, 900, 500, 400, 300, 200 amino acids, preferably at least 20, 50, 100 amino acids and up to 100, 200, 300, 400, 500 amino acids. In a preferred embodiment the repellent factor according to the invention comprises the amino acid sequence selected from SEQ ID NO: 2, 3, 4, 5, 6, 7, 8 and 9 and preferably a polypeptide, the amino acid sequence of which is shorter than the mature SLIT3 protein. Preferably, the amino acid sequence is shorter than 1523 or 1522, preferably shorter than

-15-

1491 or shorter than 900 amino acids in length, preferably between 200 and 900 amino acids in length or more preferably between 220 and 760, between 240 and 520, between 250 and 300 amino acids in length. In a further preferred embodiment the repellent factor according to the invention
5 comprises at least the amino acid sequence of SEQ ID NO: 6, 7, 8 or 9 and the amino acid sequence is shorter than the mature SLIT3 protein.

The term "mature SLIT3 protein" refers to the human SLIT3 protein without a signal peptide sequence. Preferably, the mature SLIT3 protein starts at position 33 or 34 of SEQ ID NO: 1 or starts at position 1 or 2 of SEQ ID NO:
10 2.

In some embodiments, the repellent factor comprises the amino acid sequence selected from SEQ ID NO: 1 to 9 or has at least 85% homology to the amino acid sequence of SEQ ID NO:1 to 9, wherein the amino acid sequence preferably is shorter than the mature SLIT3 protein.

15 In another preferred embodiment, the repellent factor according to the invention comprises at least the amino acid sequence of SEQ ID NO:1 from position 34 to 917, position 47 to 863, position 66 to 857, position 279 to 863, position 279 to 857, position 279 to 724, position 279 to 504, position 311 to 432, position 335 to 432 or position 312 to 437. More preferably, the
20 repellent factor according to the invention comprises at least the amino acid sequence of SEQ ID NO:1 from position 308 to 413, position 308 to 317, position 331 to 340, position 344 to 352, position 357 to 366, position 380 to 389, position 394 to 402 or position 404 to 413 or a combination thereof.

Further preferred are the repellent factors, in which one or more Cys are
25 substituted by another amino acid, in particular, by Ala. Preferred are repellent factors comprising a sequence selected from SEQ ID NO:1 to 9, in particular, from SEQ ID NO:2 to 9, in which one or more Cys are substituted by another amino acid, in particular, by Ala. A preferred Example of such repellent factor is SEQ ID NO:21 which is derived from SEQ ID NO:9 by
30 substituting Cys in position 85 with Ala.

-16-

In a preferred embodiment, the repellent factor is non-glycosylated at least in the second leucine-rich repeat domain or homologous leucine-rich repeat domain.

5 The term "second leucine-rich repeat domain" of the present invention refers to a conserved leucine-rich amino acid sequence present in SLIT proteins. The leucine-rich repeat (LRR) domain of SLIT3 consist of four LRRs (LRR1-4) flanked by amino- and carboxy-terminal conserved regions (LRR-NR and LRR-CR) (Itoh, et al., 1998; Howitt, et al., 2004; Hohenester, et al., 2006). The second leucine rich domain encompasses the amino acid sequence
10 between position 248 and 467 of SEQ ID 1. Homologous leucine-rich repeat domain refer to an amino acid sequence with conserved amino acid exchanges of the second leucine-rich repeat domain, the homologous region of other SLIT family members such as SLIT1 and SLIT2 and/or a homology of 80%, 85%, 90%, 95% to the amino acid sequence between position 248
15 and 467 of SEQ ID 1.

In a further preferred embodiment, the repellent factor according to the present invention is non-glycosylated, more preferably the repellent factor is a recombinant *E.coli* derived protein.

20 In a further preferred embodiment, the degenerative disease preferably degenerative cartilage disease is selected from the group consisting of degenerative disc disease, meniscus tears, anterior crucial ligament (ACL) injury, arthritis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, rhizomelic pseudoarthritis, rheumatoid polyarthritis, villonodular synovitis or synovitis.

25 In another preferred embodiment, the articular cartilage is hyaline articular cartilage.

In a preferred embodiment, the non-articular cartilage is selected from the group of meniscus and intervertebral disc.

30 In some embodiment, the pharmaceutical composition of the present invention and/or the pharmaceutical composition comprising the isolated

-17-

polypeptide of any of the embodiments of the invention is an injectable formulation which preferably is injected locally near the defect or non-systemically or even more preferably administered intra-articularly, into the synovia and/or into the synovial fluid.

- 5 In a further preferred embodiment, the pharmaceutical composition of the present invention and/or the pharmaceutical composition comprising the isolated polypeptide of any of the embodiments of the invention is an injectable formulation administered systemically e.g. by intravenous administration.
- 10 In a specific embodiment, the pharmaceutical composition is administered locally to the area in need of treatment. This may be achieved by for example local infusion during surgery, topical application, by injection, by means of a catheter or by means of an implant, said implant being porous or non-porous.
- 15 Other routes for administration of pharmaceutical compositions covered by the present invention are intradermal, intramuscular, intraperitoneal, subcutaneous, intranasal or oral routes. The dosage range adopted will depend, among others, on the route of administration and on age, weight and condition of the patient being treated.
- 20 A suitable amount of polypeptide administered to a patient is preferably from 0.001 mg/kg body weight of patient to 100 mg/kg body weight of patient, preferably 0,01 mg/kg body weight of patient to 20 mg/kg body weight of patient, more preferably from 0.01 to 10 mg/kg body weight of patient, most preferably 0,1 mg/kg to 1 mg/kg body weight of patient.
- 25 The pharmaceutical composition comprising the repellent factor of the present invention and/or the pharmaceutical composition comprising the isolated polypeptide of any of the embodiments below and above may be in a variety of formulations e.g. pharmaceutical acceptable carriers. Examples of suitable pharmaceutical carriers are described in "Remington's
30 Pharmaceutical Sciences, 18th Ed., 1990, ISBN #: 0912734027, Mack Pub

-18-

Co). The formulation may deliver the repellent factor rapidly or may be a sustained release formulation. Such compositions may contain a therapeutically effective amount of the repellent factor together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration. Regardless of the route of administration, the repellent factor is formulated into acceptable unit dosage forms by conventional methods known to the person skilled in pharmaceutical art. In a preferred embodiment, the repellent factor is formulated in accordance with routine procedures as a pharmaceutical composition for intravenous administration to human beings. Typically, the pharmaceutical compositions for intravenous administration include a solubilization agent e.g. sterile isotonic aqueous buffer with or without a local anesthetic such as lignocaine. Generally, the ingredients are supplied either separately or mixed together in unit dosage forms for example as a dried lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachet. In case where the pharmaceutical composition is to be administered by infusion, it can be dispersed with an infusion bottle containing a solubilization agent.

In a preferred embodiment the formulation includes aqueous liquid, saline solution, solid, semi-solid, liquid, pasty, putty dosage forms, dispersions, suspensions, gels, liposomes, a matrix, a shape stable material, *in situ* setting materials, a tissue adhesive biomaterial, injectable and minimal invasive as well as implantable application form.

In some other embodiment, the pharmaceutical composition of the present invention is selected from the group consisting of an aqueous liquid, a solid, semi-solid, paste, putty, liposomes, a shape stable material, a matrix, an *in situ* setting material, a tissue adhesive biomaterial.

In a preferred embodiment, the pharmaceutical composition comprises the repellent factor and/or the isolated polypeptide of the repellent factor encapsulated in liposomes. The liposomal formulations have the advantage over solutions in that the protein is protected against degradation within the

-19-

biological environment in addition to a longer duration of the therapeutic agent and slower clearance at the site of application.

Liposomes generally comprise an enclosed lipid droplet having a core typically containing a compound in an aqueous medium. In certain
5 embodiments, the compound is chemically bound to a lipid component or simply contained within the aqueous inside compartment of the liposome.

Pharmaceutical compositions provided according to the present invention are preferably provided as dried liposomal compositions that can be reconstituted to produce liposomes encapsulating the repellent factor and/or
10 the polypeptide, preferably the liposomal preparation are dried reconstituted vesicles (DRVs) which upon reconstitution in an aqueous solution form protein encapsulated liposomes. The liposomal composition used herein is for example dry granular products which upon addition of water disperse to form multi-lamellar liposomal formulations comprising the biological active
15 component. Advantageously, stability problems such as aggregation or oxidation are avoided by using dried liposomes.

Suitable lipids for use in the formulations which are present individually or in mixtures include neutral or positively charged lipids such as cholesterol, phosphatidylcholine, hydrogenated phosphatidylcholine, distearoyl-
20 phosphatidylcholine, sphingomyelin, dioleoyl phosphatidylcholine, dioleoylphosphatidylglycerol, phosphatidylglycerol, dimyristoylphosphatidylcholine, dipalmitoylcholine, gangliosides, ceramides, phosphatidylinositol, phosphatic acids, dicetylphosphate, dimyristoyl phosphatidylcholine, stearylamine, dipalmitoyl phosphatidylglycerol and other similar lipids.
25 Preferably the lipid mix is charged. The liposomal formulation is typically a mixture of at least two lipids such as cholesterol and phosphatidylcholine and more usually three or more lipids.

The present invention further provides an isolated polypeptide having at least 85% amino acid sequence homology, preferably 90%, more preferably
30 95% homology to the amino acid sequence of SEQ ID NO: 1 to 9 and wherein the amino acid sequence is shorter than the mature SLIT3 protein, preferably wherein the isolated polypeptide is shorter than 1523, preferably

-20-

shorter than 1491 or shorter than 900 amino acids in length, preferably between 200 and 900 amino acids in length or more preferably between 200 and 760, between 200 and 520, between 200 and 300 amino acids in length. In a preferred embodiment, the isolated polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 9, more preferably the isolated polypeptide contains the amino acid of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 and wherein the amino acid sequence is shorter than the mature SLIT3 protein, preferably wherein the isolated polypeptide is shorter than 1523, preferably shorter than 1491 or shorter than 900 amino acids in length, preferably between 200 and 900 amino acids in length or more preferably between 220 and 760, between 240 and 520, between 250 and 300 amino acids in length.

In a preferred embodiment, the present invention further provides an isolated polypeptide which comprises at least the amino acid sequence of SEQ ID NO:1 from position 34 to 917, position 47 to 863, position 66 to 857, position 279 to 863, position 279 to 857, position 279 to 724, position 279 to 504, position 311 to 432, position 335 to 432 or position 312 to 437.

More preferably, the present invention provides an isolated polypeptide which comprises at least the amino acid sequence of SEQ ID NO:1 from position 308 to 413, position 308 to 317, position 331 to 340, position 344 to 352, position 357 to 366, position 380 to 389, position 394 to 402 or position 404 to 413 or a combination thereof.

In a preferred embodiment, the isolated polypeptide and/or the repellent factor of the present invention is pegylated. The thus modified polypeptide and/or the repellent factor has a biological half-life time greater than the unmodified agent and therefore improves efficacy of the agent for medical treatment of degenerative disorders. In addition tendency towards aggregation of the protein is reduced.

Pegylation can be achieved via stable covalent bonds between an amino or sulfhydryl group on the protein and a chemically reactive group (carbonate, ester, aldehyde, or tresylate) on the polyethylenglycol (PEG). The resulting

-21-

structure may be linear or branched. PEG reagents are for example described in Roberts et al. (Roberts, et al., 2002). Other pegylation agents are but are not limited to methoxypoly(ethylene glycol) (mPEG), methyl PEO₁₂ maleimide PEG, amine-reactive, methyl-capped polyethylene oxide
5 (PEO)-containing modification agents (Methyl PEO_n-NHS Esters, n=4, 8,12).

Also modified and/or stabilized peptides can be employed such as stabilized peptides having modified bondings to prevent degradation of the peptides.

The present invention further provides a pharmaceutical composition comprising an isolated polypeptide or repellent factor of any of the above
10 embodiments.

In another preferred embodiment, the invention provides a pharmaceutical composition of any of the embodiments wherein the protein is combined with a carrier, implant or delivery system.

The carrier, implant or delivery device used in the invention is preferably
15 biocompatible in that it is not toxic and does not elicit inflammatory reactions in the body. They can include a matrix or scaffold structure and may be a solid, a liquid, a gel, a paste or other injectable form. Preferably, the carrier, implant or delivery device comprise a hydrogel as for example described in WO2005/113032, in particular injectable hydrogels, sulphated hyaluronic
20 acid, a highly substituted carboxymethylcellulose and salts thereof, alginate, hydroxypropylalginate, chitosan, hydroxethylstarch, collagen, gelatin, reverse thermal gels (e.g. Pluronic F128), a chitosan based thermosensitive copolymer (e.g. chitosan-Pluronic® hydrogel), a porous silk scaffold, a plurality of microspheres, a liposomal formulation and a hydroxyapatite fiber
25 mesh.

In a preferred embodiment, the carrier according to the present invention comprises a fibrin gel composed of platelet-rich plasma, platelet enriched plasma with biodegradable gelatin hydrogel, fibrin/hyaluronic acid
30 composites, factor encapsulated gelatine hydrogel microspheres, injectable biodegradable hydrogel composites comprising for example polymers such

-22-

as oligo(poly(ethyleneglycol) fumarate, polylactide (PLA) /polyglycolicacid (PGA) and poly epsilon capronolactone.

Preferably, the carrier comprises a chitosan-glycerol phosphate or an *in situ* blood clot stabilized with chitosan-glycerol phosphate solution.

- 5 In another embodiment, the delivery system comprises a degradable hydrogel scaffold such as gelatin microparticles, polymer based biodegradable and biocompatible hydrogels, a polymer-reinforced hybrid clot or other polymer based biodegradable and biocompatible implants or delivery systems for delivery of the repellent factor and/or isolated
10 polypeptide of the present invention.

Preferred polymers of the invention comprise collagen, chondroitin sulfate, hyaluronic acid, hyaluronate, hyaluronic ester, hyaluronic benzylester, oligo(poly)(ethylene glycol) fumarate, chitosan, chitosan glycerol phosphate, including tri-copolymers such as gelatin/chondroitin-6-sulfate/hyaluoran tri-
15 copolymer or any combination thereof.

In a further embodiment, the pharmaceutical composition is formulated as a sustained release formulation. In another embodiment, the pharmaceutical composition is formulated as a sustained release formulation which provides intermittent release.

- 20 Treating the degenerative disease can be further improved by stabilizing a blood clot formed in the lesion of the degenerated tissue with a polymer that has thrombogenic activity and stimulates the wound repair process. Therefore, in a further preferred embodiment, the pharmaceutical composition further comprises at least one substance, additive or matrix with
25 thrombogenic activity.

In a further preferred embodiment, the polymer is thrombogenic and/or stimulates platelet aggregation and degranulation.

- In another preferred embodiment, the polymer is hemostatic, more preferably, the polymer is hemostatic and stimulates revascularization of the
30 wound tissue and/or connective tissue repair.

-23-

In another embodiment, the polymer is solubilized under physiological conditions and forms a solid implant after mixture with whole blood. These implants have the advantage to adhere more to the tissue defect than normal clots and therefore improve cartilage regeneration.

- 5 In some embodiment, the pharmaceutical composition of any of the embodiments of the present invention further comprises cartilage cells, preferably wherein the cartilage cells are chondrocytes.

Co-encapsulation of human chondrocytes derived from various tissues e.g. human ear, nasal, rib, inner meniscus cells (IMCs), fat pat cells (FPCs),
10 synovial membrane cells (SMCs), articular chondrocytes or other chondrocyte tissue, mesenchymal stem cells (MSCs) and/or bone marrow stroma cells, in either of the above mentioned embodiments or a combination thereof is also an embodiment of the invention. In particular, these cells are expanded with or without growth factors to enhance
15 chondrogenesis of different chondrocyte types and then induce to form cartilage tissue after implantation.

Mesenchymal stem cells (MSCs)" according to the present invention are a primitive or resting cell population that resides in many mature skeletal tissues as uncommitted mesenchymal progenitor cells. MSCs are flexible
20 and have the ability to differentiate towards several mature tissue types, including cartilage, bone, fat and other tissue, depending on the environment and biological signals provided to these resting cells. MSCs are available from many autologous sources, including bone marrow, blood, muscle tissue and fat that can be harvested to isolate these cells without significant donor
25 site morbidity or immunogenic potential.

Furthermore, the problem underlying the present invention is solved by the use of a polypeptide of any of the above embodiments for manufacturing of a pharmaceutical composition for the prevention and/or treatment of a disease such as a degenerative disease. In a preferred embodiment, the
30 degenerative disease is a degenerative disease as specified in of any of the above embodiments. Preferably the degenerative disease is arthritis such as

-24-

osteoarthritis or rheumatoid arthritis including chronic or acute rheumatoid arthritis.

In another embodiment the invention relates to the use of a repellent factor according to any of the above mentioned embodiments for influencing the migratory behavior of mesenchymal stem cells.

Furthermore, the invention encompasses the use of a repellent factor according to any of the above mentioned embodiments for induction of migration or attraction of mesenchymal stem cells.

Preferably, the invention relates to the use of a repellent factor according to any of the above mentioned embodiments for the induction of cartilage formation and/or for stimulation of the proliferation or differentiation of chondrocytes.

The invention further comprises an isolated polypeptide comprising the consensus sequence $C(Y)_3CYC(Y)_6C(Y)_{99}C(Y)_{47}CYC(Y)_{20}C(Y)_{20}C(Y)_{20}C(Y)_{13-22}C$.

Further preferred is an isolated polypeptide comprising the consensus sequence $C(Y)_3CYC(Y)_6C(Y)_{99}C(Y)_{47}CYC(Y)_{20}C(Y)_{20}C(Y)_{20}C(Y)_{13-22}C$, wherein C denotes cysteine and Y denotes any amino acid, wherein at least one cysteine is substituted by any other amino acid except cysteine. By replacing at least one cysteine by another amino acid folding and/or dimer formation of the sequence can be influenced.

The invention further provides a pharmaceutical composition for gene therapy for the prevention and/or treatment of a degenerative disease comprising a DNA of a repellent factor gene or parts thereof, which encodes for a repellent factor or active fragment thereof which has a therapeutic effect on a degenerative disease such as one disease described within the invention.

According to the pharmaceutical composition of the present invention, the DNA of a repellent factor gene or parts thereof can be provided preferably with a retroviral vector, adenoviral vector, adenovirus-associated viral (AAV)

-25-

vector, herpes simplex virus (HSV) vector, murine leukemia virus (MLV) vector, lentivirus vector or a plasmid which can be expressed in a human cell or a recombinant cell which has been transformed or transduced with a recombinant vector comprising the DNA encoding for the repellent factor or
5 active fragment thereof in order to apply the repellent factor to the impaired tissue locally (local administration), systemically or continuously.

The term "DNA repellent factor gene" means a DNA encoding for a repellent factor or active fragment thereof. It is not limited to the natural isolated DNA but also includes any form of modification of the natural nucleotide sequence
10 which after translation forms a polypeptide of any of the embodiments of the present invention or which forms a polypeptide under maintenance of the activity of the repellent factor preferably in addition to elements for expression regulation operably linked to the nucleic acids (e.g. inducible promoter elements and/or enhancer element(s)) suitable for the purpose of
15 the present invention. The recombinant vector also may comprise a nucleotide sequence for a signal peptide required for secretion of the polypeptide by the gene out of the cell. The vector may further comprise one or more selection marker gene or reporter gene.

The DNA may be derived from a human, mouse, rat or other vertebrate
20 repellent factor. Nucleotide sequences encoding these proteins are readily available to a skilled person. Preferably, the DNA is derived from a human repellent factor. The sequences can be for example found in GenBank, SwissProt and other databases. They may be cDNA or genomic DNA and clones comprising the nucleic sequences can be derived from depositories
25 such as the ATCC or can be cloned by PCR approach or can be chemically synthesized. The DNA sequence may be further optimized for codon usage. Examples of DNA sequences for repellent factors are GI4507060 (Slit1), GI4759145 (Slit2), GI11321570 (Slit3), GI:148613883 (Netrin1) or nucleic acid fragments thereof.

30 Preferably, the recombinant cells are autologous fibroblasts of the synovium, skin, bone marrow origin, lymphocytes or dendritic cells. Most preferably, the

-26-

recombinant cells are autologous fibroblasts of the synovium, skin or dendritic cells.

It is one embodiment of the present invention to provide a pharmaceutical composition and use thereof for locally delivering nucleic acid molecules encoding for the repellent factor or an active fragment thereof to an affected tissue such as arthritic joints in particular to the rheumatoid synovium. In particular, the pharmaceutical composition and use thereof enables an efficient transfection or transduction of nucleic acid molecules encoding a repellent factor in cells of tissue such as synovial cells in a therapeutically effective amount and over a sufficient period of time with preferably high expression of the therapeutic protein in the target cells.

Preferably, the vector or plasmid is not integrated into the genome of a transduced cell e.g. to express the protein in an extrachromosomal manner.

Preferably, the vector or plasmid is stably integrated into the genome of a transduced cell and preferably provides long term and/or sustained release of the therapeutic protein.

Local administration of the pharmaceutical composition to the affected tissue such as arthritic joint refers preferably to *in vivo* or *ex vivo* administration to the arthritic synovium. Delivery of the nucleic acid *ex vivo* comprises transduction of autologous or non-autologous synovial cells with the viral vector or transfection with a plasmid comprising the nucleic acid encoding the repellent factor or parts thereof, selecting the transduced cells and administering the transduced cells to the rheumatoid joint of the subject by for example reimplantation, injection or reinfusion of cells into the joint of the subject. *In vivo* administration refers to the direct administration of the vector or plasmid comprising the nucleic acid encoding the repellent factor or parts thereof to the joint of the subject e.g. by intra-articular injection. The advantage of local administration is that less gene product and thus fewer vector is needed to treat individual joints.

For systemical delivery the vector is preferably introduced at extra-articular

-27-

locations by for example intramuscular, subcutaneous or intravenous injection by single or repeated injection or infusion.

Preferably, the pharmaceutical composition of the above embodiments further comprises additional pharmaceutical acceptable excipients such as
5 but not limited to physiological liquids, water, saline, buffers, emulsifiers, stabilizers, lyophilisation agents and the like.

As an alternative the pharmaceutical composition for gene therapy for the prevention/and or treatment of a degenerative disease comprising a DNA of a repellent factor gene or parts thereof, which encodes for a repellent factor
10 or active fragment thereof is introduced into liposomes and is injected directly into the area of the joint, where the liposomes fuse with the synovial cells resulting in an *in vivo* expression of the repellent factor of any of the embodiments above.

Preferably, the pharmaceutical composition of any of the above
15 embodiments is injected as naked DNA.

The invention is further illustrated by the Figures and Examples which are merely illustrative and are not constructed as a limitation of the scope of the present invention.

20 **FIGURE 1** shows the inhibitory effect of NETRIN1 on the migration of synovial fibroblasts. The effect of NETRIN1 on OA (A) and RA (B) synovial fibroblasts in passage 3 and passage 10 was measured in Boyden Chamber assays. NETRIN1 was applied to the upper or the lower chamber, respectively.

25 **FIGURE 2** shows the migration of OASF and RASF after addition of Slit3 analyzed in a Boyden Chamber Migration Assay.

Slit3 incubation (0.1 µg/ml) decreased migration of OASF in early passages (P3 and P4) to about 60% (Slit3 in upper chamber together with OASF) compared to control and about 40% (Slit3 in lower chamber). In RASF

-28-

(P3/P4), Slit3 reduced migration to about 45% (Slit 3 in upper chamber) and 50% (Slit3 in lower chamber) respectively.

FIGURE 3 shows the influence of Slit3 on the proliferation of synovial fibroblasts of osteoarthritis (OASF) patients and rheumatoid arthritis (RASf) patients. Slit3 incubation (0,1 µg/ml) together with OASF and RASF decreased growth of OASF and RASF slightly.

FIGURE 4 shows the differentiation of Human Mesenchymal Stem Cells (HMSC) upon Slit3 addition.

A Slit3 increased aggrecan expression after 7 days of treatment.
B TGFβ induced differentiation of HMSCs towards chondrocytes was further enhanced by Slit3 treatment analyzing MIA expression.

FIGURE 5 shows the expression of the LRR2 construct expressed with the RTS 500 system (Roche Molecular Biochemicals) on SDS PAGE.

Lane 1: recombinant protein of RTS 500 (without His-Tag) as control 10 µl
 Lane 2: recombinant SLIT3 fragment LRR2 10µl
 Lane 3: recombinant SLIT3 fragment LRR2 1µl
 Lane 4: recombinant mouse Slit3 (250ng; R&D Systems)

FIGURE 6 shows the SLIT3 mediated inhibition on the migration of Mel Im (R&D Systems) and A 375 cells using Slit3 (R&D Systems), LRR2, LRR2 dNC.

FIGURE 7 and 8 show reduced migration of OASF and RASF in a Boyden Chamber Migration Assay (according to example 2 and 5) in early passages upon treatment with Slit 3 (R&D Systems, Fig. 7, Fig. 8 lane 2, LRR2 (Fig. 7, Fig. 8 lane 3), LRR2 dNC (Fig. 7, Fig. 8 lane 4), LRR 2dNCmut (Fig. 8 lane 5) and LRR3 (Fig. 8 lane 6). Lane 1: control

FIGURE 9 shows the inhibition of cartilage destruction measured as GAG protein level in the supernatant of OA synovial fibroblasts after co-culture with different repellent proteins.

-29-

Lane 1: cartilage control (without OA synovial fibroblasts)

Lane 2: OA synovial fibroblasts

Lane 3: OA synovial fibroblasts + NETRIN1

Lane 4: OA synovial fibroblasts + mSlit3

5 Lane 5: OA synovial fibroblasts + LRR2 dNCmut

Example 1: Isolation of primary human synovial fibroblasts

Synovial tissue samples were obtained from synovectomy and arthroplastic surgery from four patients with RA and four patients with OA (Clinic of Orthopedic Surgery, Schulthess Clinics, Zuerich, Switzerland) after informed
10 consent and approval of the local ethics committee. The diagnosis of OA was made according to clinical and radiological criteria. All RA patients fulfilled the American College of Rheumatology 1987 criteria for the diagnosis of RA. In OA patients, synovial tissue was obtained from hip and
15 knee joints exhibiting end-stage joint space narrowing, whereas in RA patients, material was sampled from wrist or proximal interphalangeal joints with the joints exhibiting florid synovitis and/or arthritic destructions. Synovial tissue was minced mechanically, washed extensively in sterile phosphate-buffered saline (PBS) and digested with 150 mg/ml Dispase II (Boehringer Mannheim, Mannheim, Germany) for 1h at 37 C under continuous agitation.
20 The resulting cell suspension was seeded into tissue culture dishes and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco Life Technologies, Basel, Switzerland) containing 10% fetal calf serum and 100 U/ml penicillin per 100 µg/ml streptomycin in a humidified atmosphere at 37 C followed by the addition of 5% CO₂. In the third, fifth and tenth
25 passage, adhering fibroblasts were washed, trypsinized and used for RNA isolation or in the assays. As a control dermal fibroblasts were used.

Example 2: Inhibition of migration of primary human synovial fibroblasts from RA and OA patients

The inhibitory potential of repellent factors on the migration of synovial
30 fibroblasts from osteoarthritis and rheumatoid arthritis patients was analyzed in a migration assay.

-30-

The effect of the repellent factors on cell migration was analyzed using a Boyden Chamber assay containing polycarbonate filters with 8 µm pore size (Costar, Bodenheim, Germany), essentially as described previously (Jacob, et al., 1995). Filters were coated with gelatin. The lower compartment was filled with fibroblast-conditioned medium, used as a chemo-attractant. Cells were harvested by trypsinization for 2 min, resuspended in DMEM without FCS at a density of 2×10^5 cells/ml and placed in the upper compartment of the chamber. After incubation at 37°C for 4 hours, the filters were collected and the cells adhering to the lower surface fixed, stained and counted. The repellent factor e.g. recombinant NETRIN1 (human recombinant NETRIN1 protein derived from HEK293 cells, amino acid 28-604, N-terminal Flag-tag, Alexis Biochemicals), Slit3 (recombinant mouse Slit3 protein, Ser27 – His 901, R&D Systems) was added either to the upper or the lower chamber of the system in a concentration of 0.1 µg/ml.

It is known that phenotypical changes in synovial fibroblasts occur during cultivation *in vitro* and that these cells lose their aggressive phenotype gradually while grown *in vitro* (Zimmermann et al., 2001). Therefore, the inventors desired to obtain freshly isolated synovial fibroblast cells with phenotypic features as close as possible to the configuration observed *in vivo* and analyzed the effect of repellent factors on the migration using cells in early and late passages.

These experiments clearly demonstrated the inhibition of these factors on the migration of freshly isolated synovial fibroblasts from human synovial tissue of patients with RA and OA.

The results are depicted in Figs. 1 and 2.

As depicted in Fig. 1 (A) and Fig. 1 (B), there was a strong inhibition of RA and OA synovial fibroblast migration in early passages (passage 3) whereas fibroblasts derived from healthy donors or in high passages were not affected. The effects were seen after addition of recombinant NETRIN1 to the upper and to the lower chamber, respectively, indicating that not chemotaxis but molecular processes of migration were affected by NETRIN1.

-31-

These findings presented here suggest that NETRIN reduces the migratory ability of the cells, potentially by repulsion of the cells.

As depicted in Fig. 2, migration of OASF and RASF and the influence of the guidance cue Slit3 on the cells were analyzed. In early passages (P3 and P4), a strong inhibitory effect of Slit3 on both OASF and RASF (n=2) compared to untreated cells was determined. This effect was evident not only in presence of Slit3 in the upper chamber together with the SF, but also in combination of Slit3 with the fibroblast-conditioned medium as chemoattractive in the lower chamber.

10 **Example 3: Influence of recombinant Slit3 and NETRIN1 on proliferation of OASF and RASF**

Proliferation was measured using the Cell Proliferation Kit II (Roche) according to the supplier's instructions. It is based on a colorimetric (XTT) measured non-radioactive quantification of cell proliferation performed for four days. Recombinant Slit3 or NETRIN1 was added in a concentration of 0.1 µg/ml. Cell proliferation assays revealed a calculated doubling time of about 4.5 days (d) for OASF and 3.5 d for RASF. Slit3 treatment resulted in a weak inhibition of proliferation, cell growth decelerated for about 1 d for OASF and RASF after Slit3 treatment (Fig.3). A weak inhibition of cell growth was also seen after NETRIN1 treatment; however, the effect was not significant.

Example 4: Differentiation of Human Mesenchymal Stem Cells (HMSC)

To evaluate the effect of Slit3 on differentiation HMSC were cultured in pellet culture and treated with Slit3, TGFβ or Slit3/TGFβ, respectively. Slit3 increased expression of AggreCAN after 7 days of treatment and MIA after 21 days of treatment without induction by TGFβ (Fig. 4). TGFβ-induced differentiation of HMSCs towards chondrocytes was slightly enhanced by Slit3 treatment analyzing MIA expression (Fig. 4B).

Example 5: Expression of SLIT3 constructs in an RTS system

30 To analyse whether also fragments of SLIT3 can be used as a

-32-

pharmaceutical active ingredient for manufacturing of a pharmaceutical product for treatment of RA various human SLIT3 constructs are generated and tested in functional assays according to Example 1 to 4 using Mel Im cells, A375 cells primary human RASF and OASF cell and HMSC and Example 9. All constructs were made by PCR amplification of cDNA derived from RNA isolated from human chondrocytes or synovia fibroblasts from multiple donors. Construct LRR1-4 (SEQ ID NO: 7) was amplified using the primers 5' GAC CAT ATG GCC CCT GCC CCA CCA AGT GTA CC 3' and 5' GAC CCC GGG ATT GCA TTT GGC CAC AAT G 3', LRR2 (SEQ ID NO: 8) using the primers 5' GAC CAT ATG ATC TCC TGC CCT TCG CCC TGC 3' and 5' GAC CCC GGG GAA GCA CTC GCT GCT GAA CC 3', LRR2 dNC (SEQ ID NO: 9) using the primers 5' GAC CAT ATG ATC GTC GAA ATA CGC CTA GAA C 3' and 5' GAC CCC GGG TGG GTT TTG GGC TAA GTG GAG 3', and LRR3 using the primers 5' GAC CAT ATG GAC CTC GTG TGC CCC GAG AAG 3' and 5' GAC CCC GGG GCT CAG CTG GCA GCT ACT CTC 3'. LRR2 dNCmut (SEQ ID NO: 21), in which the remaining Cys was exchanged by an Ala (Cys85Ala), was cloned by site-directed mutagenesis using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, Amsterdam, Netherlands) and the primers 5' CCA ACA AGA TCA ACG CCC TGC GGG TTA ACA CGT TTC AGG 3' and 5' CCT GAA ACG TGT TAA CCC GCA GGG CGT TGA TCT TGT TGG 3'. Fragments are cloned into the NdeI and SmaI site of the expression vector pIVEX2.3-MSC and the insert sequences were verified by sequencing. C-terminal HIS tagged SLIT3 proteins are expressed in an RTS 500 system (Roche Molecular Biochemicals). *In vitro* transcription and translation were performed according to the instruction of the manufacturer. Protein expression was analyzed by Western blot analysis (SDS PAGE) using different amounts (1 µl, 10 µl) of protein generated with the RTS 500 expression system (Fig. 5). The activity of the protein fragments generated with the RTS 500 system was analyzed in a migration assay a) using Mel Im (described by Jacob, et al., 1995), b) A375 (CRL1619, ATCC) cells and c) OASF and RASF cells of Example 2 using a Boyden Chamber assay as

-33-

described in Example 2 except that 1 µl of protein generated according to the RTS 500 system was added either to the upper or the lower chamber of the system. As depicted in Fig. 6 A and B, Fig. 7 and Fig. 8 there was an inhibition of the migration of all cell lines using Slit3, LRR2, LRR2 dNC and LRR2 dNCmut. Surprisingly, the LRR2 dNC protein which lacks the N- and C-terminal stabilizing part of the SLIT3 protein sequence as well as LRR2 dNCmut (Cys85Ala variant) also inhibits the migration of synovial fibroblast cells indicating that only the minimal binding domain of the protein comprising part of the secondary structure is sufficient for the inhibitory effect.

Example 6: Animal models for treatment of rheumatoid arthritis (RA)

The migration and destructive behaviour of synovial fibroblasts and the influence of repellent factors of the present invention can be analyzed in different animal models. A well-established model to analyse new biologicals for the treatment of rheumatoid arthritis (RA) is a collagen-induced arthritis (CIA) model in rodents e.g. rat or mice (Bendele et al., 2000). RA is induced in female rats by intradermal/subcutaneous injection of bovine type II collagen in Freund's incomplete adjuvants. As rats develop the disease the repellent factor is administered in a sustained delivery system of e.g. liposomes or saline (PBS) vehicle either subcutaneously or intraperitoneally. Treatment can be analysed by determination of ankle joint swelling and measure of inflammation as well as by histopathological scoring of the joints after decalcification.

An alternative model is the severe-combined immunodeficient mouse (SCID) co-implantation model. Human RASF and fresh human cartilage are-co-implanted together with an inert sponge (e.g. collagen sponge) under the kidney capsule of SCID mice and these are maintained for 60 days (Huber, et al., 2006). The RASF cells invade and destroy the human articular cartilage.

A third model to be used is the antibody-induced arthritis model, where an intraperitoneal injection of a mixture of anti-type II collagen monoclonal

-34-

antibodies in LPS/PBS induces RA in mice e.g. Balb/c mice (Terato, et al., 1992).

A fourth model is the chronic OVA-induced or antigen induced arthritis model in rabbits (Podolin, et al., 2002). Animals are sensitized by s.c. injection of
5 10 mg of OVA in 2 ml of CFA and boosted at 3- to 4- week intervals by intrascapula administration of OVA in IFA. Positive skin tested animals are administered OVA in PBS into the knee joint. Rabbits are dosed p.o. with the repellent factor e.g. SLIT3 fragment or with vehicle. To measure the effect of the compound synovial fluids for total cell counts, differential cell analyses,
10 eisosanoid/cytokine measurements and knee diameter using callipers were determined. Blood sample are taken before and after administration of the compound.

In case of testing a compound for its involvement in alteration of synovial fibroblast migration and treatment option for arthritis said compound can be
15 added to the system optionally in saline solution or as a pharmaceutical formulation such as a liposomal preparation.

Example 7: Animal model for treatment of osteoarthritis (OA)

An animal model for treatment of osteoarthritis is the rabbit anterior cruciate ligament transection model. Under general anaesthesia and sterile
20 conditions, the knee joint of rabbits are approached via a medial parapatellar incision (between the medial collateral ligament and patellar ligament). The patella is displaced laterally and the infrapatellar fat pad is mobilized and retracted to expose the entire anterior cruciate ligament.

The surgery and injection schedule is as follows: 6 animals per group (sham,
25 vehicle and repellent factor). The animals will be subjected with 1 or multiple (e.g. 5) injections preferably every 10 days. Animals are killed 10 days after the final injection and X-rays are obtained.

Subsequently, samples are prepared for histological examination upon with safranin O-fast green and hematoxylin and eosin staining (e.g. fixed with
30 10% neutral buffered formaline, decalcification in EDTA and paraffin

-35-

embedding).

Example 8: *In vivo* gene delivery

Gene therapy vectors can be constructed using conventional methods of molecular biology. Non-viral and viral transduction of synovial fibroblasts is
5 described for example in Meinecke et al., 2007 incorporated by reference herewith. Local intra-articular gene therapy can be analyzed in various animal models of rheumatoid arthritis and osteoarthritis such as but not limited to those described under Examples 6 and 7.

10 Each of the patent applications and patents cited in this text, as well as each document or reference cited in this text are hereby expressly incorporated herein by reference and may be employed in the practice of the invention ("herein cited references"). Each of the cited documents or references as well as patent applications and patents and patents cited within the cited
15 references is hereby expressly incorporated herein by reference.

While preferred embodiments have been illustrated and described, it should be understood that modifications can be made in accordance with ordinary skill in the art without departing from the invention in its broader aspect as defined by the claims.

20 **Example 9: Inhibition of GAG release**

Samples of human cartilage (cube edge length 5mm, 4 cubes each treatment (50mg)) were incubated with or without OA synovial fibroblasts (50.000 cells). Samples with OA SF were additionally treated with either NETRIN1, mSlit3 or LRR2 dNCmut, respectively. Supernatant was taken
25 after 6 days of co-culture and GAG concentration was measured using a commercially available GAG-ELISA (Euro-Diagnostica, Malmo, Sweden; Wieslab sGAG quantitative Kit). Results are shown in Fig. 9.

-36-

Reference List

- 5 Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ and
Edwards CK, III (2000) Combination benefit of treatment with the cytokine
inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor
necrosis factor receptor type I in animal models of rheumatoid arthritis.
Arthritis Rheum **43(12)**:2648-2659.
- 10 Hohenester E, Hussain S and Howitt JA (2006) Interaction of the guidance
molecule Slit with cellular receptors. *Biochem Soc Trans* **34**:418-421.
- Howitt JA, Clout NJ and Hohenester E (2004) Binding site for Robo
receptors revealed by dissection of the leucine-rich repeat region of Slit.
Embo J **23**:4406-4412.
- 15 Huber LC, Distler O, Turner I, Gay RE, Gay S and Pap T (2006) Synovial
fibroblasts: key players in rheumatoid arthritis. *Rheumatology (Oxford)*
45:669-675.
- 20 Itoh A, Miyabayashi T, Ohno M and Sakano S (1998) Cloning and
expressions of three mammalian homologues of Drosophila slit suggest
possible roles for Slit in the formation and maintenance of the nervous
system. *Brain Res Mol Brain Res* **62**:175-186.
- Jacob K, Bosserhoff AK, Wach F, Knuchel R, Klein EC, Hein R and Buettner
R (1995) Characterization of selected strongly and weakly invasive sublines
of a primary human melanoma cell line and isolation of subtractive cDNA
clones. *Int J Cancer* **60(5)**:668-675.
- 25 Katoh Y and Katoh M (2005) Comparative genomics on SLIT1, SLIT2, and
SLIT3 orthologs. *Oncol Rep* **14(5)**:1351-1355.
- Klagsbrun M and Eichmann A (2005) A role for axon guidance receptors and
ligands in blood vessel development and tumor angiogenesis. *Cytokine*

-37-

Growth Factor Rev **16**:535-548.

5 Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, Ohgushi H, Wakitani S and Kurosaka M (2007) Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. *Osteoarthritis Cartilage* **15**(2):226-231.

Little MH, Wilkinson L, Brown DL, Piper M, Yamada T and Stow JL (2001) Dual trafficking of Slit3 to mitochondria and cell surface demonstrates novel localization for Slit protein. *Am J Physiol Cell Physiol* **281**:C486-C495.

10 Meinecke,I., Rutkauskaite,E., Cinski,A., Muller-Ladner,U., Gay,S., and Pap,T. (2007). Gene transfer to synovial fibroblast: methods and evaluation in the SCID mouse model. *Methods Mol. Med.* **135**: 393-412.

15 Morlot,C., Hemrika,W., Romijn,R.A., Gros,P., Cusack,S., and McCarthy,A.A. (2007). Production of Slit2 LRR domains in mammalian cells for structural studies and the structure of human Slit2 domain 3. *Acta Crystallogr. D. Biol Crystallogr.* **63**: 961-968.

Pap T (2003) New insights into integrin signalling: implications for rheumatoid arthritis synovial fibroblasts. *Arthritis Res Ther* **5**:154-155.

Pap T (2007) [Regulation of apoptosis in aggressive fibroblasts.]. *Z Rheumatol* **66**:239-242.

20 Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, Hagen TR, Kajikawa O, Marshall LA, Hay DW and Sarau HM (2002) A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. *J Immunol* **169**:6435-6444.

25 Roberts MJ, Bentley MD and Harris JM (2002) Chemistry for peptide and protein PEGylation. *Adv Drug Deliv Rev* **54**:459-476.

-38-

Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH and Stuart JM (1992) Induction of arthritis with monoclonal antibodies to collagen. *J Immunol* **148(7)**:2103-2108.

5 Vargesson N, Luria V, Messina I, Erskine L and Laufer E (2001) Expression patterns of Slit and Robo family members during vertebrate limb development. *Mech Dev* **106**:175-180.

Yasuda T (2006) Cartilage destruction by matrix degradation products. *Mod Rheumatol* **16**:197-205.

10 Zimmermann T, Kunisch E, Pfeiffer R, Hirth A, Stahl HD, Sack U, Laube A, Liesaus E, Roth A, Palombo-Kinne E, Emmrich F and Kinne RW (2001) Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. *Arthritis Res* **3**:72-76.

15

-39-

Claims

- 5 1. Use of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect.
- 10 2. Use according to claim 1 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect, wherein the repellent factor is selected from the group of Slits, Netrins, Ephrins and Semaphorins.
- 15 3. Use according to claim 1 or 2 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect, wherein the repellent factor a) has at least 85% homology to the amino acid sequence of SLIT3 (SEQ ID NO:1) or NETRIN1 (SEQ ID NO:10), b) is an active fragment of SLIT3 or
20 NETRIN1 or c) has at least 85% homology to the amino acid sequence of the active fragment of b).
- 25 4. Use according to any of claims 1 to 3 of a repellent factor, wherein the repellent factor comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 to 9 or 21 or has at least 85% homology to any of the amino acid sequences of SEQ ID NO:1 to 9 or 21 and wherein the amino acid sequence is shorter than the mature SLIT3 protein.
- 30 5. Use according to any of claims 1 to 4 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect, wherein the repellent factor is a fragment of SLIT3 (SEQ ID NO:1).

-40-

6. Use according to claim 1 or 2 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect, wherein the repellent factor is an agonist or antagonist of a ROBO receptor, DCC or UNC receptor.

7. Use according to any of claims 1 to 6 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect associated with infiltration or migration of synovial fibroblasts into articular or non-articular cartilage and/or associated with pannus formation.

8. Use according to any of claims 1 to 7 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect being a degenerative disease associated with decreased attachment of cells to articular or non-articular cartilage.

9. Use according to any of claims 1 or 8 of a repellent factor for the manufacture of a pharmaceutical composition for the prevention and/or treatment of a cartilage defect being a degenerative disease, wherein the disease is selected from the group consisting of degenerative disc disease, meniscus tears, anterior crucial ligament (ACL) injury, arthritis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, rhizomelic pseudoarthritis, rheumatoid polyarthritis, synovitis or villonodular synovitis.

10. Use according to any of claims 1 to 9 of a repellent factor, wherein the repellent factor is non-glycosylated at least in the second leucine-rich repeat domain or homologous leucine-rich

-41-

repeat domain.

11. An isolated polypeptide having at least 85% amino acid sequence homology to any of the amino acid sequences of SEQ ID NO:1 to 9 or 21 and wherein the amino acid sequence is shorter than the mature SLIT3 protein for the prevention and/or treatment of a cartilage defect.
12. A pharmaceutical composition for the prevention and/or treatment of a cartilage defect comprising a repellent factor as defined in any of claims 1 to 10 or a polypeptide of claim 11.
13. The pharmaceutical composition of claim 12, wherein the polypeptide is combined with a carrier, an implant or a delivery system.
14. A pharmaceutical composition comprising a repellent factor as defined in any of claims 1 to 10 or a polypeptide of claim 11, further comprising at least one substance, additive or matrix with thrombogenic activity.
15. A pharmaceutical composition comprising a repellent factor as defined in any of claims 1 to 10 or a polypeptide of claim 11, further comprising cartilage cells.
16. The pharmaceutical composition of claim 15, wherein the cartilage cells are chondrocytes.
17. Use according to any of claims 1 to 10 of a repellent factor or a pharmaceutical composition according to any of claims 12 to 16, wherein the pharmaceutical composition is an injectable

-42-

formulation.

18. Use according to claim 17 of a repellent factor or a pharmaceutical composition according to claim 17, wherein the pharmaceutical composition is an injectable formulation for administration intra-articularly and/or into the synovia.
19. Use or according to any of claims 1 to 10, 17 or 18 of a repellent factor or a pharmaceutical composition according to any of claims 12 to 16, wherein the pharmaceutical composition is selected from the group consisting of an aqueous liquid, a solid, semi-solid, paste, putty, liposomes, a shape stable material, a matrix, an *in situ* setting material, or a tissue adhesive biomaterial.
20. An isolated polypeptide comprising the consensus sequence: $C(Y)_3CYC(Y)_6C(Y)_{99}C(Y)_{47}CYC(Y)_{20}C(Y)_{20}C(Y)_{20}C(Y)_{13-22}C$, wherein C denotes cysteine and Y denotes an amino acid for the prevention and/or treatment of a cartilage defect.





Figure 1/9






Figure 2/9

**Figure 3/9**

Aggrecan MIA





↑
↑
unspecific



Figure 5/9




Figure 6/9




Figure 7/9




Figure 8/9




Figure 9/9